News for AVITA Medical, Inc. (AVH.AX)

On June 10, 2025, AVITA Medical (RCEL) received a reaffirmation of its 'Buy' rating from D. Boral Capital. This rating was issued by analyst Jason Kolbert, who

AVITA Medical (RCEL) recently showcased compelling findings on their RECELL technology at the British Burn Association Annual Meeting. Researchers presented dat

Hospital stays reduced by 6.2 days (35.7%) with RECELL technology compared to traditional methods. Cost savings of approximately $300 million over a 5-y

AVITA Medical (RCEL) continues to draw confidence from analysts as highlighted by the recent report from D. Boral Capital. Analyst Jason Kolbert has maintained

VALENCIA, Calif., June 03, 2025 (GLOBE NEWSWIRE) -- AVITA Medical, Inc. ( RCEL, ASX: AVH), a leading therapeutic acute wound care company delivering a portfol

AVITA Medical's RECELL platform, including RECELL GO, awarded 'Best New Technology Solution ”“ Surgical' at the 2025 MedTech Breakthrough Awards. Recog

TD Cowen has revised its price target for Avita Medical (RCEL), reducing it from $15 to $12.50, while maintaining a Buy recommendation. The adjustment follows A

Revenue: $18.5 million for Q1 2025, a 67% increase compared to Q1 2024.Gross Profit Margin: 84.7% for Q1 2025, down from 86.4% in Q1 2024.Operating Expenses: $

May 08, 2025 / 08:30PM GMTOperator Good day, and thank you for standing by. Welcome to AVITA Medical First Quarter 2025 Earnings Conference Call. (Operator Inst

The following slide deck was published by AVITA Medical, Inc.

The ASX200 is set to rise today, following an optimistic performance on US stocks following news of a US trade deal framework with the UK

AVITA Medical (RCEL) announced a substantial increase in its first-quarter revenue, reporting $18.52 million compared to $11.1 million in the previous year. The

VALENCIA, Calif., May 08, 2025 (GLOBE NEWSWIRE) -- AVITA Medical, Inc. ( RCEL, ASX: AVH), a leading therapeutic acute wound care company delivering transforma

VALENCIA, Calif., April 17, 2025 (GLOBE NEWSWIRE) -- AVITA Medical, Inc. ( RCEL, ASX: AVH), a leading therapeutic acute wound company delivering transformativ

AVITA Medical (NASDAQ: RCEL, ASX: AVH) to reveal Q1 2025 financial performance on May 8, 2025, post U.S. market close. Conference call and webcast scheduled

BOSTON and ATLANTA, April 14, 2025 (GLOBE NEWSWIRE) -- Inhibikase Therapeutics, Inc. ( IKT) (”œInhibikase” or ”œCompany”), a clinical-stage pharmaceutic

Sixteen abstracts to present real-world findings and clinical innovations across AVITA Medical's expanded portfolio, including RECELL, Cohealyx, and PermeaDerm

AVITA Medical (RCEL) to present 16 abstracts at ABA 2025, showcasing groundbreaking burn and wound care data. Significant findings include over 6,000 re

**media[590882]**